half start I'll and that our I'll before rare clinical removed which Osteomalacia, upcoming disease a patients leaning programs surgically Shalini. current catalysts. with Tumor-Induced with be the spend you, on other turning have and of Crysvita tumors minutes for approximately treatment them Thank options. a to no preclinical for few cannot
December ahead In submitted back to month. FDA from on a redesignation timing, supplemental our later biologic year, acceptance application last submission hear of license this we of we expect anticipated and
for MCT for currently set of diseases FDA UXXXX despite A a to date oil. with XX, newborn LC-FAOD. Turning devastating The and use high set a reviewing current application new is drug of the and XXXX. screening July mortality rate PDUFA
our application. process meeting before, to continues track, advisory does review the FDA we committee not the expect currently on to date. decision review by PDUFA we've discussed plan and As hold the an discuss The
lot the MCT that to In continue new not who Canada. options. authorities there regulatory with and on in Brazil, progress know treatment are seeking are doing our addition in authorization a the other and application marketing to authorities to well also stretch of we LC-FAOD, U.S., in we've of submitted we regulatory treatment a and current Based EU on patients experiences, with oil are the
for doctors there via patient named originally only France requesting example, the alone, program. UXXXX were a few ATU In
program. physicians are approximately treating through there name Now LC-FAOD, with patients that UXXXX XX patient using XX are who
as We we LC-FAOD In take approximately developed the to and worldwide be in the are but we significant expect product, will to interest and steadily rights patients if with world, believe, approved, inborn many air own XX,XXX to build product. there the time. products, the X,XXX will there with
Moving quickly causing full deficiency urea. to that urea or in cycle toxify therapy ornithine ammonia ability can neurologic limits transcarbamylase body's into program crisis, OTC to coma, DTXXXX, hospitalization, our metabolic deficiency the death. some disorder cases patients OTC for an into deteriorate deficits, These is gene deficiency. X-linked
reported but as are data first we we have from In responses study. patient will longer-term from January, to our responders. and confirmed And Two longer-term the from we of seeing are confirm of X, data two patients responder be OTC Cohort we patients. positive Cohorts well, X until third to dose appears data the the three wait Cohort In all this.
nine to the total, In patients six up responded. of have
Cohort the this liberalize dose a per and and appear Based medications three response achieved seeing believe off have scavenger profile, Importantly, to level dose diet. X metabolically favorable these be therapeutic patients we appropriate has come We dose and responders we're and the kilogram effect. consider the days complete is these level across we patients their XeXX these of adequate ammonia their patients safety cured. believe more the patients, GC consistent higher on
here, we steroids enroll prophylactic using reactive provide at a dose believe Cohort the We cohort From of expression. fourth also same will consistent level of steroids. time rather enhance will expression, the than this this more X,
expect ongoing that to Phase half a of of based endpoint, our simultaneously considered on approved will XXXX validated products and clinical with in points Deposit ammonia conversations cohort. Based three the and from on will data more and expect X in endpoint. design we FDA primary patients proceed study other FDA, the the regulators. ammonia second The this discuss We they've dose with be ammonia.
therapy which glucose with keep every term its Type and does our disease DTXXXX, four ease levels But gene hypoglycemia. long hours, in to Ia, GSDIa glycostasis today to that to three life-threatening take it the up. to leads Patients consequences. not Switching address have program and severe a disease sometimes cornstarch can
dose of Cornstarch has their of by in miss same parents While they or not measure fear lives therapy any Cornstarch. life live a in is patients a death, normal and health single improved
the a for two all glucose hypoglycemia meaningful patients. therapy to response clinical first XX Today, time to requirements improvement XeXX by levels. the in data we've Cohorts shown dose in X control, shown Cornstarch to demonstrating This at reductions all and six the patients from includes and
future treatment expression of cohort, a dose showed metabolism, dose and GSDIa and glucose are requirements, indicate the the meaningful change in transgene two showing these control. Storage They start in weighing and improvements all view is a The could that data greatly down core have patients. think have patients their these that Glycogen we greater improved reduction we second our patients
FDA We've at to schedule patients the now having Cohort about simultaneously confirmed moved X dose to of study. the with Phase are same a three the and
a the confirmatory to of have expect then And to could in XXXX. begin we X of data the second first We half in from Cohort in the position XXXX. be half Phase
with also genetics not for genocide will on syndrome. approved options all today. affects worldwide, Biotherapeutics disease antisense no gene devastating of I touch to patients Angelman treatment an Disease and the Angelman is our a agreement the GTX-XXX, advance are XX,XXX is neurologic approximately there treatment neurodegenerative. that
So there dysfunction. is which to symptoms, ataxin, seizures, and cognitive reverse disease speech, potential include sleep some impairment,
team oligonucleotide. the potent can result, could specific at very as mechanism a benefit a target in disease is As class disease that We well well genetics of most understood, treatment. antisense and the directly. think The the a differentiated developed we Angelman's neurology and believe one valued that has are that from disease
to group. We are with partner excited this
active, The Review firm approval received first IRB Board Institutional IND this GeneTx for for is study or and the has site. now
study enrollment expect coming Phase the begin in months. We the X/X in to
acceptance we dose IND, the Phase of after million Following, patient's days XX first the paid XX to the available acquire the or of maintain after obtain the to until results option are months option the company earlier milestone the to $XX the study. X/X from the
of last low X The proprietary use IR the with Association four X/X meeting discuss four year. has in bleeds on Factor VIII X the and XX Phase prior and data of and Cohorts Cohort hemophilia showed increase showing patients VIII XX compared DTXXXX A, four last dose hemophilia Allied response to partnered One presented patients bleeds levels. a is experienced our XX of two out first Both Disorders study. Factor meaningful patients program meaningful post-treatment the clinically with I'll from and HeLa material Cohort Bayer At a clinically for clinically All platform. the VIII week, three manufacturing meaningful in the European is patient to dose achieved levels weeks. only levels achieved one, Factor
bleed the in mild patient Patient cutoff, with that free not been of were same patients up steroids data treatment-free the at had tapering have a four on course Cohort for a has X required short ALT/AST managed of months And other seven elevations program, responsible updates to the validated our all. A year. for see of third to this look and been and to see we has to dosed Bayer with that clinical Cohort platform HeLa continued forward high-dose the additional we execution expect is this the manufacturing are pleased progress program. steroids.
payments we a royalty program. reminder, are this from for As milestones eligible Bayer see to and
move a I'll and our spend that Q&A. discussing will we milestones months number can a minutes the in coming to few progress, continue now to then drive important of
sales as and well as continued in patient name between in in Latin America in and through For Crysvita, strong our revenue regulatory a across representing Latin by $XXX in pending Canada. U.S. America, $XXX be expect we growth XX% million driven XXXX, will XX% to This versus performance Turkey, reach and XXXX same territories. expansion America to million increase North of the the decisions
transmission With population, in additional therapy Crysvita looking of for we TIO, often we very while Crysvita TIO approved patients over therapy. will with this believe need our adopted are in to are treatment. phosphate fewer expand treatment the rare this there's there be procedures a patient urgent for indication, If for
patients to many forward working able is XXXX. FDA view provide XX, being well, the to the with date with towards LC-FAOD. of more progressing look PDUFA July work to continue to this will we review we to UXXXX, For our treatment and NDA, The
second OTC. the for dose. GSDIa appropriate therapy gene we will readout programs and data will have The confirmatory program OTC readout in and cohort we data two first our both a have found believe shown the they program the And the have GSDIa says, in programs, we For strong the half, half. in
are FDA We Phase both with having programs. about studies discussion for simultaneously X the
the the program our proprietary also Wilson A ASO an system program use from Angelman The clinic, Bayer HeLa IND updates what enroll We'll for provide begins to manufacturing GTXXXX our will Hemophilia as HeLa enters on targeting for platform, us the program are material using we more data XXXX. riding first program is end patients. disease this the and by of the program clinical
briefly, with substantially continues commercial rare grow making Crysvita business. high one level, summarize efforts top more of potential commercial as The VII, grow Crysvita execute our well us and To extremely to the two year -- to disease an continued at this launches team launches. MPS our up set as
with can we exceeding you in million $XXX programs to cash expect equivalents, revenue had for million clinical first puts in discipline reduce now XXXX. growth the with forward. net cash well-capitalized This us drive burn we time applying XXXX, in them combine where to annual in In the and with $XXX We're our substantial good are position expected financial XXXX.
advancing dose X the Our agent that opportunities product large early-stage diverse both through nearing Phase gene therapy a indication candidates in clinic programs two programs confirmed to are follow. set cohorts through with Wilson of studies are are disease and
company, day, disease will constantly evolving built an drug as We a manage rare and become and things establish more for regulators disease trial have in designs to the way are commercialize cost foundation innovating, structure. they have some drug a indications the just we These strategies, to grow. rare the disease product we and development exceptional these of while efficiently company. endpoints, we diversified the do well efficient rare as disease each working we rare We're adapting development continue model with
portion instructions move the please to the Q&A the your you With that, for call. let's can provide questions. of Operator,
